Among diagnostics companies, Vijaya Diagnostic Centre topped the gainers’ chart, followed by Dr. Lal PathLabs, Metropolis Healthcare, and Thyrocare Technologies.
Decline in revenue along with higher operating expenses, largely marketing and advertisement related, will lead to moderation in operating margins to pre-pandemic levels.
Of the $10 billion worth market, standalone centres account for 48% market share, followed by hospital labs with 37% share and national chains with 5% share.
Healthcare facilities were forced outside hospital boundaries in the pandemic, leading to a rise in home diagnostics, but there is a need of a more analytical approach in managing, gathering data
Ameera Shah's Metropolis Healthcare is all set to acquire Hitech Diagnostics Centre. Here's Fortune India's earlier story on how Shah is transforming her fast-growing pathlab company.
The Pune-based company is pioneering the production of test kits to screen for Covid-19. With fresh funding, it hopes to rapidly ramp up capacity.
Technologies like artificial intelligence and machine learning can help in diagnosis, treatment protocol development, drug development, personalised medicine, and patient monitoring and care.
The stock opened at ₹960 per share on the BSE, a premium of 9% over its issue price of ₹880.
